Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.
Launched by SANTEN SAS · Apr 2, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how myopia, or nearsightedness, affects people’s quality of life, especially those who developed it in childhood and are now adults. The aim is to understand how myopia and its complications, like cataracts or glaucoma, impact daily activities and overall well-being. Researchers will also gather information about healthcare resources, such as treatment costs and access to care, to help improve future healthcare models. It’s important to note that this study will not evaluate the effectiveness of myopia treatments or track any side effects.
To participate, individuals must either be adults with myopia and its complications or be parents of children aged 5 and older who have myopia. The types of myopia range from low to high, based on how severe the condition is. However, children under 4 years old and individuals whose eye problems are not related to myopia will not be included in the study. Participants can expect to share their experiences and insights about living with myopia, contributing to valuable research that may help others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parents (or other proxy) of children or adolescents aged 5 years or older suffering from myopia (low, moderate, or high myopia) defined by their spherical equivalent (SER): Low myopia is from -0.5 D (inclusive) to -3.0 D (inclusive), Moderate myopia is from -3.0 D to -6.0 D (inclusive) and High myopia is \<-6.0 D.
- • Adults suffering from myopia and its complications such as: cataract, macular degeneration, open-angle glaucoma, retinal detachment, and legal blindness/severe visual impairment.
- • Patients where myopia is a known or likely contributing factor to the complication.
- Exclusion Criteria:
- • Parents (or other proxy) of children aged 4 years and below.
- • Patients where the complication is likely unrelated to myopia (e.g., cataract caused by diabetes) will be excluded
About Santen Sas
Santen SAS is a leading pharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. With a strong commitment to improving the quality of life for patients with eye diseases, Santen focuses on research-driven solutions in areas such as glaucoma, retinal disorders, and dry eye disease. Leveraging extensive expertise in ophthalmology, Santen SAS engages in collaborative partnerships and clinical trials to advance therapeutic options and enhance patient care. The company is dedicated to scientific excellence and aims to provide high-quality treatments that address unmet medical needs in the global eye care market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported